US National Institutes of Health Prioritization of SARS-CoV-2 Variants
- Univ. of Cambridge (United Kingdom)
- Univ. of California, Riverside, CA (United States)
- National Institutes of Health (NIH), Rockville, MD (United States)
- Ben Gurion Univ. of the Negev, Beer Sheva (Israel)
- Walter Reed Army Institute of Research, Silver Spring, MD (United States); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD (United States)
- Charité–Universitätsmedizin and German Center for Infection Research, Berlin (Germany)
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Erasmus Medical Center, Rotterdam (Netherlands)
- Icahn School of Medicine at Mount Sinai, New York, NY (United States)
- Univ. of Missouri, Columbia, MO (United States)
- Univ. of Cambridge (United Kingdom); Charité–Universitätsmedizin and German Center for Infection Research, Berlin (Germany)
- Univ. of Wisconsin, Madison, WI (United States)
- Argonne National Laboratory (ANL), Argonne, IL (United States); Univ. of Chicago, IL (United States)
- J. Craig Venter Institute, Inc., La Jolla, MD (United States); Univ. of California, San Diego, CA (United States)
- J. Craig Venter Institute, Inc., La Jolla, MD (United States)
- Massachusetts Inst. of Technology (MIT), Cambridge, MA (United States); Harvard Univ., Cambridge, MA (United States)
- J. Craig Venter Institute, Inc., La Jolla, CA (United States); Univ. of California, San Diego, CA (United States); La Jolla Institute for Immunology, CA (United States); Global Virus Network, Baltimore, MD (United States)
Since late 2020, SARS-CoV-2 variants have regularly emerged with competitive and phenotypic differences from previously circulating strains, sometimes with the potential to escape from immunity produced by prior exposure and infection. The Early Detection group is one of the constituent groups of the US National Institutes of Health National Institute of Allergy and Infectious Diseases SARS-CoV-2 Assessment of Viral Evolution program. Here, the group uses bioinformatic methods to monitor the emergence, spread, and potential phenotypic properties of emerging and circulating strains to identify the most relevant variants for experimental groups within the program to phenotypically characterize. Since April 2021, the group has prioritized variants monthly. Prioritization successes include rapidly identifying most major variants of SARS-CoV-2 and providing experimental groups within the National Institutes of Health program easy access to regularly updated information on the recent evolution and epidemiology of SARS-CoV-2 that can be used to guide phenotypic investigations.
- Research Organization:
- Argonne National Laboratory (ANL), Argonne, IL (United States)
- Sponsoring Organization:
- Centers for Disease Control and Prevention (CDC); National Institutes of Health (NIH); U.S. Army; USDOE Laboratory Directed Research and Development (LDRD) Program
- Grant/Contract Number:
- AC02-06CH11357
- OSTI ID:
- 2433839
- Journal Information:
- Emerging Infectious Diseases, Journal Name: Emerging Infectious Diseases Journal Issue: 5 Vol. 29; ISSN 1080-6040
- Publisher:
- Centers for Disease Control and Prevention (CDC)Copyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Dissecting Phenotype from Genotype with Clinical Isolates of SARS-CoV-2 First Wave Variants
Nanobody screening and machine learning guided identification of cross-variant anti-SARS-CoV-2 neutralizing heavy-chain only antibodies